Atea Pharmaceuticals, Inc. AVIR
4.28 USD +0.08 (+1.79%)
Nov 11, 2026, 12:50 PM EST
4.06 Day range 4.34
2.87 52-week range 6.45
- YTD
- +19.75%
- 1 year
- +26.48%
- Market cap
- 343.30M
- EPS (ttm)
- -1.95
- Shares out
- 84.46M
- Forward P/E
- -2.12
- YTD return
- +19.75%
- 1-year return
- +26.48%
- Volume
- 127.83K
- Avg volume
- 285.38K
- Open
- 4.22
- Previous close
- 4.20
- Day's range
- 4.06 – 4.34
- 52-week range
- 2.87 – 6.45
- Beta
- 0.17
- Price target
- 7.40 (+73.1%)
- Earnings date
- Aug 7, 2024
5D -0.03 (-0.69%)
Key statistics
- Enterprise value
- -211.54M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.60
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -17.91M
- Total cash
- 482.81M
- Total debt
- 1.83M
- Return on equity
- -33.46%
- Short % of float
- 4.34%
- 50-day average
- 3.31
- 200-day average
- 3.59
Analyst view
Price target (mean) 7.40 +73.1% upside
Now 4.28
- Target (low)
- 6.20
- Target (mean)
- 7.40
- Target (high)
- 8.00
Ratings (0m) 3 1 buy · 1 hold · 1 sell
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell1
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.28963.
Financials — quick view
AVIR Revenue — quarterly 0
AVIR Net income — quarterly -32.16M
AVIR EPS — quarterly -0.40
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.50 | -0.37 | +0.13 | +26.00% |
| Aug 7, 2024 | Jun 1, 2024 | -0.77 | -0.48 | +0.29 | +37.66% |
| Aug 7, 2024 | Jun 1, 2024 | -0.77 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.61 | -0.75 | -0.14 | -22.95% |
| May 14, 2024 | Mar 1, 2024 | -0.61 | — | — | — |
| Feb 28, 2024 | Dec 1, 2023 | -0.44 | -0.47 | -0.03 | -6.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2024 | Morgan Stanley | up | Underweight | Equal-Weight |
| Aug 10, 2023 | JP Morgan | down | Neutral | Underweight |
| Mar 16, 2023 | JP Morgan | main | — | Neutral |
| Jan 27, 2023 | SVB Leerink | main | — | Market Perform |
| Jan 24, 2023 | Morgan Stanley | main | — | Underweight |
| Aug 15, 2022 | Morgan Stanley | main | — | Underweight |
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ateapharma.com
News
Atea Pharmaceuticals, Inc. (AVIR) Q3 2026 Earnings Call Transcript 
What Atea Pharmaceuticals (AVIR) Said on Its Q3 Earnings Call 
CORRECTION: Atea Pharmaceuticals Q3 EPS $(0.40) Beats $(0.42) Estimate 
Atea Pharmaceuticals Q3 2026 Earnings Call Transcript 
Atea Pharmaceuticals Q3 EPS $0.40 Beats $(0.42) Estimate 
Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update 
Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital 
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7 
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial - Atea Pharmaceuticals Says Topline Data From C-BEYOND Phase 3 Trial Of Once-daily Fixed-Dose Combination Of Bemnifosbuvir and Ruzasvir for Chronic Hepatitis C Virus Infection Shows Statistical Non-Inferiority Vs. Fixed-Dose Combination Of Sofosbuvir and Velpatasvir
Your note
Sign in to keep a note on AVIR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS JEROME M. M.D. | Director | Conversion of Exercise of derivative security | Jun 13, 2024 | 33,150 |
| BERGER FRANKLIN MILAN | Director | Sale | Dec 9, 2024 | 451,897 |
| CORCORAN ANDREA J | Chief Financial Officer | Sale | Jan 31, 2024 | 670,208 |
| DUNCAN BARBARA GAYLE | Director | Conversion of Exercise of derivative security | Jun 13, 2024 | 33,150 |
| FOSTER WAYNE CPA | Officer | Sale | Jan 31, 2024 | 20,857 |
| HORGA MARIA ARANTXA | Officer | Sale | Jan 31, 2024 | 25,664 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.64% | 8,990,734 | 29.22M | Sep 29, 2024 |
| BML Capital Management, LLC | 7.87% | 6,650,000 | 21.61M | Sep 29, 2024 |
| FMR, LLC | 7.84% | 6,618,297 | 21.51M | Sep 29, 2024 |
| EcoR1 Capital, LLC | 6.44% | 5,441,896 | 17.69M | Sep 29, 2024 |
| Vanguard Group Inc | 5.74% | 4,851,218 | 15.77M | Sep 29, 2024 |
| Tang Capital Management, LLC | 5.45% | 4,607,060 | 14.97M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.80% | 2,363,327 | 7.68M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.34% | 1,978,851 | 6.43M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.51% | 1,276,333 | 4.15M | Sep 29, 2024 |
| Fidelity Growth Company Fund | 1.14% | 961,766 | 3.13M | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 0.95% | 805,352 | 2.62M | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.91% | 769,595 | 2.50M | Aug 30, 2024 |